The Food and Drug Administration rejected AcelRx Pharmaceuticals Inc.'s (Nasdaq: ACRX) needle-free pain medication device Zalviso sending the stock price plummeting $4.26 to $6.57.
FDA rejects AcelRx's Zalviso
July 28, 2014 at 15:42 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.